Summer Sale! Save 25%
Free Express Shipping
Sale Ends: 07/25
Uses
Side effects
Interactions
Precautions
- INGREZZA is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.
- Most common adverse reaction (≥5% and twice the rate of placebo): somnolence.
- Drugs Having No Clinically Important Interactions with INGREZZA
- Dosage adjustment for INGREZZA is not necessary when used in combination with substrates of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, or CYP3A4/5 based on in vitro study results.
- Somnolence: May impair patient’s ability to drive or operate hazardous machinery.
- QT Prolongation: May cause an increase in QT interval. Avoid use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval.
